Radiation Therapy and Sargramostim in Treating Patients With Advanced Solid Tumors

Completed · Phase 1/Phase 2

Conditions studied: Unspecified Adult Solid Tumor, Protocol Specific

In brief

RATIONALE: Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with sargramostim may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects of giving radiation therapy together with sargramostim and to see how well it works in treating patients with advanced solid tumors.

Key facts

Study ID

NCT00091052

Run by

Sirius Medicine

Starts

2004-07-01

Expected to finish

2006-06-01

Last updated by the study team

2013-03-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Sirius Medicine, LLC — Loveland, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.